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ABSTRACT 25	
Metabolic phenotypes of individuals are the result of genes, environment, lifestyle, diet and gut 26	
microbiota interactions. The aim of this study is to evaluate the robustness of clinical and 27	
metabolic phenotyping in identifying differential responsiveness to dietary strategies in the 28	
improvement of cardiometabolic status. Clinical phenotyping of 57 male volunteers with high 29	
cardiovascular risk factors was performed using K-means cluster analysis based on 69 30	
anthropometric and plasma biochemical parameters. Cluster validation analysis based on Dunn 31	
analysis for internal coherence and FOM analysis for external homogeneity was applied. The K-32	
means analysis produced four clusters with particularly significant clinical profiles. Basal 33	
differences on the urine metabolomic profiles among clinical phenotypes were explored and 34	
validated by OSC-PLS-DA models. Multivariate analysis (OSC-PLS-DA) of 1H-NMR spectra 35	
revealed that the model comparing the “obese and diabetic cluster” (OD-c) against the 36	
“healthier cluster” (H-c) showed the best predictability and robustness in terms of explaining the 37	
pairwise differences between clusters. When considering these two clusters, two different 38	
groups of metabolites were observed after following an intervention with wine polyphenol 39	
intake (WPI, 733 Equivalents of Gallic Acid [GAE/day] per 28 days). Cluster differences 40	
between baseline and post-intervention values of 24h-urine NMR metabolomic data were 41	
analyzed by ANOVA. Those associated to a specific metabotype (OD-c), glucose as the 42	
significantly characteristic of the group (FDR correction, p<0.01,) and lactate, betaine and 43	
dimethylamine with a trend; and those associated to wine polyphenol intervention (OD-c_WPI 44	
and H-c_WPI), tartrate (FDR correction p<0.001), and mannitol, threonine methanol, fucose 45	
and 3-hydroxyphenylacetate in a trending profile. On the other hand, 4-HPA (metabolite derived 46	
from gut microbial metabolism after wine polyphenol intake) significantly increased (FDR 47	
correction, p<0.05) for H-c_WPI compared to OD-c_WPI and basal periods (H-c_BAS and 48	
OD-c_BAS), exhibiting a metabotypic intervention effect. This study provides efficient 49	
strategies for targeting the heterogeneity in individual’s responsiveness to dietary intervention 50	
and the identification of health benefits in specific population groups. 51	
  52	
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1 INTRODUCTION 53	
Metabolic phenotypes (metabotypes) are the result of interactions among several different 54	
factors (diet, lifestyle, gut microbiota, genetics, etc.), and describe characteristic metabolic 55	
profiles reflecting the biochemistry, the physiological status, and the environmental exposure in 56	
a population (Rezzi, Ramadan et al. 2007; Holmes, Wilson et al. 2008). Applications of 57	
metabolic phenotyping in nutrition research could be very useful in terms of assigning 58	
individuals to a particular metabolic phenotype. This could help improve our understanding of 59	
the linkage between both diet and disease with the different individual metabotypes (McNiven, 60	
German et al. 2011; Kinross, Li et al. 2014). 61	
Metabolomic technologies permit the characterization of large numbers of small molecules in 62	
human biofluids. 1H-NMR-based metabolomics is a very robust technique for performing 63	
metabolomic studies, enabling the simultaneous detection and quantification of a wide range of 64	
different metabolites. Because of this, NMR-based metabolomics has been applied in a variety 65	
of disciplines. In the field of nutrition, NMR-based metabolomics has been used to identify the 66	
most significant changes in a metabolic profile arising from dietary intervention studies, dietary 67	
biomarker studies and diet related disease studies (Brennan 2014). It can also be used to identify 68	
new small molecule candidates for disease biomarkers (Rupérez, Ramos-Mozo et al. 2012; 69	
Yang, Wang et al. 2013) 70	
Cardiovascular disease (CVD) is the leading cause of mortality worldwide, with CVD-71	
associated deaths rising very quickly in low-to-middle income countries. Modifiable risk factors 72	
for CVD—which include hypertension, smoking, abdominal obesity, abnormal lipids, diabetes 73	
mellitus, stress, low consumption of fruits and vegetables, and lack of regular physical 74	
activity—are the major contributors to CVD morbidity and mortality (Dahlöf 2010). 75	
Additionally, reduced plasma HDL levels and elevated plasma TAG concentrations are known 76	
to be significant risk factors for ischemic heart disease (IHD) (Lewington, Whitlock et al. 2007; 77	
Frikke-Schmidt, Nordestgaard et al. 2008). C-reactive protein (CRP) is another CVD risk 78	
marker (Ridker, Danielson et al. 2009). In addition, high plasma levels of homocysteine are 79	
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considered to be a risk factor for vascular disease, heart failure and strokes (Kaptoge, Di 80	
Angelantonio et al. 2010). Another important risk factor is type 2 diabetes mellitus (T2D). The 81	
prevalence of T2D is increasing rapidly around the world. Clinical predictors such as body mass 82	
index (BMI), fat distribution measured by Waist-hip ratio (WHR), CRP and fasting blood 83	
glucose levels can be helpful in measuring diabetes risk (Pradhan, Manson et al. 2001; Wilson, 84	
Meigs et al. 2007; Wannamethee, Papacosta et al. 2010; Wang, Larson et al. 2011). 85	
The low incidence of coronary heart disease (CHD) in Mediterranean countries has been partly 86	
assigned to their distinct dietary habits (Dauchet, Amouyel et al. 2009). Several studies have 87	
shown an inverse association between the Mediterranean diet and the incidence of CVD 88	
(Estruch, Ros et al. 2013). As one of the main constituents of Mediterranean diet, wine and its 89	
components, especially polyphenols, may provide additional health benefits (Chiva-Blanch, 90	
Urpi-Sarda et al. 2013). In particular, the regular consumption of wine polyphenols used in this 91	
study appears to mitigate CVD risk factors, leading to reduced blood pressure (Chiva-Blanch, 92	
Urpi-Sarda et al. 2012) and inflammatory parameters (Chiva-Blanch, Urpi-Sarda et al. 2012). 93	
The health benefits of polyphenols provided by wine intake are of particular interest. In the 94	
present study, a long-term feeding trial was performed to determine changes in urinary 95	
metabolites between different metabotypes. Therefore, the aim of the present work was to 96	
classify a specific population into phenotypic groups according to their biochemical 97	
characteristics, and then to use 1H-NMR-based urinary metabolomics to observe the different 98	
metabolic responses after red wine polyphenols intake. 99	
2 MATERIAL AND METHODS 100	
2. 1 Subjects and Study Design 101	
The study was a prospective, randomized, crossover, and controlled trial (Chiva-Blanch, Urpi-102	
Sarda et al. 2012). High-risk subjects aged ≥55 years without documented CHD (CHD: 103	
ischemic heart disease—angina/recent or past myocardial infarction/previous or cerebral 104	
vascular accident, peripheral vascular disease) were recruited for the study. The subjects 105	
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included had diabetes mellitus or more than three of the following CHD risk factors: tobacco 106	
smoking, hypertension, hypercholesterolemia, plasma LDL cholesterol ≥160 mg/dL, plasma 107	
HDL cholesterol <40 mg/dL, obesity (BMI (in kg/m2) ≥30), and/or a family history of 108	
premature CHD (first-line male relatives <55 years or females <65 years). Participants had to 109	
voluntarily give signed informed consent. Subjects with a previous history of CVD, any severe 110	
chronic disease, alcoholism, or other toxic substance abuse were excluded.  111	
To fulfil the objectives of the present study, we used 1H-NMR spectroscopy to evaluate the 112	
urinary metabolomes from 57 participants between baseline and after 28 days of red wine 113	
polyphenols intake (WPI, polyphenol content:733 Equivalents of Gallic Acid [EGA/day]) in 114	
form of dealcoholized wine from a Merlot grape variety. Results of polyphenol composition 115	
analysis of the beverages are shown in Supplemental material, Table S1. The Institutional 116	
Review Board of the hospital approved the study protocol, and all participants gave written 117	
consent before participation in the study. The trial has been registered in the Current Controlled 118	
Trials in London, International Standard Randomized Controlled Trial Number 119	
(ISRCTN88720134).  120	
2.2 Anthropometric Measurements and Biochemical Analyses 121	
Anthropometric measurements and biochemical analyses were performed using standardized 122	
methods (Estruch, Martínez-González et al. 2006). BMI and WHR were measured in all the 123	
participants to evaluate their obesity status. Systolic and diastolic blood pressures as well as 124	
heart rate were also measured. Clinical parameters were tested in the blood and urine of 125	
participants at the beginning of the study (baseline) in order to characterize the biochemical 126	
status of each participant. Blood glucose levels, total cholesterol, high-density lipoprotein 127	
cholesterol (HDL), low-density lipoprotein cholesterol (LDL), LDL/HDL ratio, 128	
triacylglycerides (TAG), 24h-diuresis, plasmatic creatine, uric acid, aminotransferases, 129	
bilirubin, ferritin, C-reactive protein, albumin, enzymes (alkaline phosphatase, lactate 130	
dehydrogenase), ions (Na+, K+), as well as globulins, apolipoprotein levels, hemoglobin and red 131	
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blood cell count; with several coagulation parameters (prothrombin, thrombin, fibrinogen) were 132	
measured. In total, 69 anthropometric and biochemical baseline parameters were evaluated. 133	
These are shown in Table 1. 134	
2.3 Biochemical Biomarkers and Clinical Phenotype by a k-means Algorithm 135	
The final data set contained 69 variables from 57 samples (of the initial set of 61 individuals, 4 136	
were excluded because of incomplete data regarding clinical and anthropometric parameters). 137	
Prior to k-means analysis all variables were typified. All cluster metrics were computed with 138	
1000 different random initializations of the k-means algorithm in order to avoid local minima. A 139	
maximum number of 100 iterations were allowed in the k-means calculations. All computations 140	
were carried out using the R package for Statistical Computing v. 2.14.1. This included the 141	
statistics package for the k-means algorithm and the clValid package for the cluster validation 142	
analysis. Dunn analysis for internal coherence and FOM analysis for external homogeneity were 143	
applied to the dataset employing Euclidean distances and a k-means clustering algorithm. Our 144	
results suggest that a cluster solution consisting of 4 centers or groups (4 clusters) showed the 145	
optimal properties of internal coherence and grouping stability (the detailed methodology and 146	
the validation procedure are in the supplemental material).  147	
2. 4 Metabolomic NMR Spectroscopy 148	
2.4.1 1H-NMR sample preparation, data acquisition and processing 149	
The protocols used for this work were based on previously published methodology (Vázquez-150	
Fresno, Llorach et al. 2012). The urine samples were thawed, vortexed, and centrifuged at 151	
13,200 rpm for 5 min. The supernatant (600 µL) from each urine sample was mixed with an 152	
internal standard solution (120 µL, consisting of 0.1 % TSP (3-(trimethylsilyl)-proprionate-153	
2,2,3,3-d4, chemical shift reference), 2 mM of sodium azide (NaN3, bacteriostatic agent), and 154	
1.5 M KH2PO4 in 99 % deuterium water (D2O)). The optimized pH of the buffer was set at 7.0, 155	
with a potassium deuteroxide (KOD) solution, to minimize variations in the chemical shifts of 156	
the NMR resonances. The mixture was transferred to a 5-mm NMR tube. The processed 157	
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spectral data were bucketed in domains of 0.005 ppm and integrated using ACD/NMR 158	
Processor 12.0 software (Advanced Chemistry Development, Inc.). The spectral region between 159	
4.75 and 5.00 ppm was excluded from the data set to avoid spectral interference from residual 160	
water.  161	
2.5 Statistical Analysis 162	
2.5.1 Biochemical biomarkers and phenotyping cluster differences 163	
Clusters were performed using k-means cluster analysis as described previously. A 164	
Kolmogorov-Smirnov test (p<0.05) was used to test the normality of the all variables using 165	
SPSS, version 18.0 for Windows (SPSS®, Chicago, IL, USA). ANOVA analysis was performed 166	
to evaluate differences in the mean biochemical measurements across clusters where statistical 167	
differences were analyzed (p<0.05).  Comparisons between clusters were assessed using a 168	
Tukey post-hoc multiple comparison test. In the case of non-parametric variables, a Kruskall 169	
Wallis test was used to test significant differences. Additionally, a Mann-Whitney test was used 170	
to detect significances between clusters. All these tests were performed by SPSS, version 18.0 171	
for Windows (SPSS®, Chicago, IL, USA).  172	
2.5.2 Metabolomic cluster analysis- OSC-PLS-DA multivariate analysis 173	
Data generated from the NMR spectral integration were submitted to MetaboAnalyst (Xia, 174	
Mandal et al. 2012). Data were normalized using the sum of the spectral intensities, then log 175	
transformed and Pareto scaled. Data were then analyzed using the SIMCA-P+ 13 software 176	
(Umetrics, Umea, Sweden) by multivariate discriminant analysis OSC-PLS-DA. A pairwise 177	
comparison analysis between the four clusters was carried out. The quality of the models was 178	
evaluated by the goodness-of-fit parameter (R2X), the proportion of the variance of the response 179	
variable that is explained by the model (R2Y) and the predictive ability parameter (Q), which 180	
was calculated using seven-fold internal cross-validation (Vázquez-Fresno, Llorach et al. 2014). 181	
Validation of the OSC-PLS-DA models was carried out by a permutation test (n=200). 182	
Additional information about the methodology is provided in the supplementary data. After 183	
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untargeted analysis with baseline samples which characterized two most discriminant clusters, 184	
then, the quantification of the samples was performed for these two clusters. 185	
2.5. 3 Metabolomic phenotype analysis by ANOVA  186	
Quantified data were submitted to MetaboAnalyst in order to find possible differences between 187	
clusters after WPI and normalized (24-h urine volume normalization, cube root transformed and 188	
Pareto scaled) (Xia, Mandal et al. 2012) before further analysis. Metabolites were analyzed by a 189	
one-way ANOVA test followed by Fisher’s LSD test for multiple comparisons. The false 190	
discovery rate (FDR) test, a statistical approach to the problem of multiple comparisons, was 191	
used in this study to counter the effect of multiple testing and verify the most discriminating 192	
metabolites (Benjamini and Hochberg 1995). Box-plots were used to show the statistical 193	
differences between treatments with P values <0.05 being considered significant. Figure 1 194	
displays a summary of the steps followed in this study. 195	
2.6 Metabolite Identification and Quantification 196	
The methyl singlet produced by a known quantity of TSP (0.97mM) was used as an internal 197	
standard for chemical shift referencing (set to 0 ppm) and for quantification. The 1H-NMR 198	
spectra were analyzed using the Chenomx NMR Suite Professional Software package (version 199	
7.8; Chenomx Inc, Edmonton, ALB, Canada), which permitted both identification and 200	
quantification by manually fitting the NMR spectra to an internal metabolite database.  201	
 202	
3 RESULTS AND DISCUSSION 203	
3. 1 Characterization of Clinical Phenotypes.  204	
61 participants were initially recruited into this study; of these, 57 participants were included in 205	
the final cluster analysis (4 were removed from the study because an incomplete biochemical 206	
profile). Of the 69 baseline biochemical parameters, k-means cluster analysis classified 4 207	
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distinct phenotypic groups: cluster 1 (n= 12), cluster 2 (n= 13), cluster 3 (n= 14) and cluster 4 208	
(n= 18). Age, smoking habits, mean dietary intake, mean concentrations of biochemical 209	
parameters and statistical tests for each cluster are presented in Table 1. Cluster 1 was defined 210	
by a significantly lower systolic blood pressure (mmHg), α2-globulin (%) and neutrophil levels 211	
(%); higher total cholesterol (mg/dL), LDL cholesterol (mg/dL), apolipoprotein B (mg/dL), and 212	
apolipoprotein B/apolipoprotein A ratio (APOB/APOA), compared with all other clusters. 213	
Cluster 2 showed lower LDL/HDL ratio compared with all other clusters and significantly 214	
higher blood glucose levels compared to cluster 4. Cluster 3 was characterized by significantly 215	
higher BMI values, α2-globulin (%), β-globulin (%),albumin/globulin ratio, and homocysteine 216	
(µmol/L) levels and a lower albumin percentage (%) compared with the other clusters. In 217	
addition, CRP values were the highest in cluster 3 and statistically significant compared with 218	
clusters 1 and 4. Furthermore, glucose levels were significantly higher in cluster 3 (>126mg/dL) 219	
compared with cluster 4 (<110mg/dL). More than >126mg/dL is diagnostic of T2D following 220	
the American Diabetes Association (ADA) criteria. Cluster 3 had the highest but not statistically 221	
significant values of the WHR index, a measure of fat distribution and also a BMI>30 indicating 222	
an obese participants cluster (Apovian and Gokce 2012). There is a strong positive association 223	
between obesity (measured by BMI) and risk of T2D in men (Wannamethee, Papacosta et al. 224	
2010). In epidemiological studies, high plasma levels of homocysteine (hyperhomocysteinemia) 225	
are considered to be a risk factor for vascular disease (Welch and Loscalzo 1998), heart failure 226	
and strokes (Collaboration 2002). Among persons with T2D, the association between 227	
homocysteine levels and cardiovascular disease may be stronger than that in non-diabetic 228	
individuals (Ndrepepa, Kastrati et al. 2008). Moreover, cluster 3 showed the lowest HDL-229	
cholesterol levels and the highest TAG levels compared to the other clusters. These features are 230	
considered risk factors for IHD (Lewington, Whitlock et al. 2007; Frikke-Schmidt, 231	
Nordestgaard et al. 2008). Finally, cluster 4 showed significantly lower concentrations of TAG 232	
(mg/dL), leucocyte count (x109/L), neutrophils (x109/L), lymphocytes (x109/L) and erythrocyte 233	
sedimentation rate (mm/h) than cluster 3; also K (mEq/L) presented lower levels compared to 234	
other clusters. The elevated circulating white blood cell count (neutrophils, lymphocytes and 235	
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monocytes) has been proposed as one of a few biomarkers of potential utility for cardiovascular 236	
disease risk prediction (Horne, Anderson et al. 2005). Moreover, the erythrocyte sedimentation 237	
rate (<10 mm/h) may be indicative of inflammation and a useful additional diagnostic criterion 238	
for coronary heart disease (Yayan 2012). On the other hand, low serum potassium levels (<4 239	
mEq/L) in a propensity-matched study was associated with higher mortality and chronic heart 240	
failure (Ahmed, Zannad et al. 2007). Overall, cluster 4 had lower levels of cardiovascular 241	
disease biomarkers than all other clusters (Table 1).  242	
3.2 Clinical Phenotypes and NMR-based Metabolomic Profiles 243	
After separation of the participants into 4 biochemically distinct clusters, an OSC-PLS-DA 244	
analysis was performed to discriminate the clusters by their NMR-derived urinary profiles. The 245	
results obtained by OSC-PLS-DA showed that the most strongly discriminated clusters were 246	
cluster 3 versus cluster 4 (see Supplemental Material); for this reason, all subsequent analyses 247	
were focused on further characterizing cluster 3 which was named the “obese and diabetic 248	
cluster” (OD-c), versus cluster 4 or named the “healthier cluster” (H-c).  249	
3. 3 Metabolomic Phenotype Analysis to Responses to Wine Polyphenol Intake 250	
Table 2 presents the results from the multiple comparison ANOVA analysis comparing cluster 251	
OD-c and H-c before and after wine polyphenols intake (WPI). Several metabolites exhibited to 252	
be associated to wine polyphenols intervention including tartrate, 4-hydroxyphenylacetate (4-253	
HPA), 3-hydroxyphenylacetate (3-HPA), mannitol, methanol threonine and fucose. Further, 4 254	
metabolites presented an association to metabolic phenotype (OD-c) which includes glucose, 255	
lactate betaine and dimethylamine, associated to obesity and TD2 (Xie, Waters et al. 2012; 256	
Menni, Fauman et al. 2013). 257	
After false discovery rate (FDR) correction, tartrate, glucose and 4-hydroxyphenylacetate (4-258	
HPA) exhibited significant results. Different patterns of response were observed for these 3 259	
metabolites: Tartrate was higher for both clusters after WPI (OD-c_WPI and H-c_WPI) (wine 260	
polyphenols intervention metabolite). Glucose was higher in the baseline group and after 261	
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intervention in cluster OD-c (OD-c_BAS, OD-c_WPI) compared with cluster H-c (H-c_BAS 262	
and H-c_WPI) (metabolic phenotype related metabolite) characteristic for cluster OD-c. Finally, 263	
4-HPA showed higher urinary excretion after WPI among subjects H-c_WPI than those in OD-264	
c_WPI and at baseline (OD-c_BAS, H-c_BAS), exhibiting a distinct post-intervention 265	
metabolic response in individuals for different clusters (metabotypic intervention effect). Box-266	
plots show the statistical differences observed for these metabolites by multiple comparison 267	
ANOVA analysis (Figure 2).  268	
Tartrate is the major organic acid in grapes and so it is also present in wine (Son, Kim et al. 269	
2008; Son, Hwang et al. 2009). Recently, it has been proposed to be a biomarker of wine 270	
consumption for both interventional and epidemiological studies (Vázquez-Fresno, Llorach et 271	
al. 2014). The tartrate urinary excreted amounts for OD-c_WPI were 1.06±0.19 mmols 272	
(84.57±14.58 µM/mM creatinine), as well as H-c_WPI 1.29±0.29 µmols (107.89±16.69 273	
µM/mM creatinine) in 24h-urine samples (Table 2). Similar to our results, a recent study 274	
reported a tartrate concentration of 91.8µg/mg creatinine (73.69 µM/mM creatinine) measured 275	
after 10h of acute wine intake (200 ml) (Regueiro, Vallverdú-Queralt et al. 2013). Additionally, 276	
the presence of this metabolite at statistically significant levels in both groups after WPI  277	
demonstrated a global compliance by all individuals in this intervention study. 278	
The presence of glucose in urine has long been used as an indicator of diabetes mellitus 279	
(Urakami, Kubota et al. 2005). T2D is characterized by the presence of glucose in urine, 280	
obesity, high levels of homocysteine and CRP, which are all characteristics of cluster OD-c 281	
subjects (Table 1). Moreover, there is a strong positive association between obesity (measured 282	
by BMI) and T2D risk (Wannamethee, Papacosta et al. 2010). Glucose excretion amounts for 283	
volunteers corresponding to the OD-c were 14.04±7.56 mmols (2157.79±1108.56 µM/mM 284	
creatinine) and 13.78±7.85 mmols (1613.70±1042.12 µM/mM creatinine) in 24h-urine samples 285	
for the OD-c_BAS and OD-c_WPI groups, respectively. These values were significantly higher 286	
than concentrations found in normal urine (12.5 - 58.4 µM/mM creatinine) (Bouatra, Aziat et al. 287	
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2013). When reported values of glucose in urine are ≥100 mg/dl (5.5 mM) it is considered to be 288	
a positive test for diabetes (Urakami, Kubota et al. 2005).  289	
Lastly, 4-hydroxyphenylacetate (4-HPA) is a metabolite involved in tyrosine and phenylalanine 290	
metabolism. Also, 4-HPA is a compound that is known to be increased in urine after 291	
consumption of wine (Vázquez-Fresno, Llorach et al. 2012), chocolate (Martin, Rezzi et al. 292	
2009), or cranberries (Prior, Rogers et al. 2010). This is because it is also a metabolic byproduct 293	
of polyphenol degradation by gut microbiota (Moco, Martin et al. 2012), particularly F. 294	
prausnitzii, Bifidobacterium, Clostridium difficile, Subdoligranulum, Lactobacillus sp. are 295	
described to be responsible of metabolism of 4-HPA (Nicholson, Holmes et al. 2012). The 4-296	
HPA excretion amount for the differential response cluster (H-c_WPI) was 0.28±0.03 mmols 297	
(25.35±1.48 µM/mM creatinine), significantly higher than excretion values described in the 298	
literature in normal conditions (1.4-14.6 µM/mM creatinine) (Bouatra, Aziat et al. 2013). It has 299	
been described that obese and diabetic people experience changes in gut microbial metabolites 300	
as a result of these cardiovascular related pathologies (Shen, Obin et al. 2013). Some studies 301	
found a decrease of Bifidobacterium, F. prausnitzii, and some species of Clostridium and 302	
Lactobacillus in obese (Tagliabue and Elli 2013) and diabetic subjects (Everard and Cani 2013). 303	
These findings are in agreement with our results, as lower levels of 4-HPA were found in cluster 304	
OD-c than in cluster H-c after wine polyphehols intake.  305	
 306	
4 CONCLUSIONS 307	
The present study has shown that phenotypic analysis using an unsupervised clustering 308	
technique (k-means analysis) can identify clusters according with their biochemical profiles. 309	
The two most discriminating clusters were named according to their clinical parameters and 310	
identified as the “obese and diabetic cluster” (OD-c) and the “healthier cluster” (H-c). 311	
Moreover, metabolomic phenotyping using NMR detected a distinct metabolic response 312	
between individuals grouped in these phenotypic clusters. In particular, comparisons between 313	
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OD-c and H-c exhibited different levels of excretion of 4-HPA after wine polyphenols intake. 314	
Likewise, a metabolite linked with a specific metabotype (glucose) and another metabolite 315	
linked with dietary intervention (tartrate) were also observed. According to our results subjects 316	
in OD-c could have altered the gut metabolism compared to individuals of H-c. Lastly, this 317	
approach showed that clinical phenotyping combined with metabolomic analysis can produce 318	
interesting quantitative results, providing new insights about the relationship between diet, gut 319	
microbiota and health. 320	
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TABLES 471	
Table 1. Biochemical and anthropometrical parameters of subjects and mean baseline 472	
concentrations of individuals clusters. P-values of ANOVA test (ï) for parametric variables and 473	
Kruskall Wallis test (♦) for non-parametric variables, (p<0.05) for both tests. Superscript 474	
numbers (1,2,3,4) indicate differences between number cluster shown, in Tukey post-hoc test (for 475	
parametrical variables) and Mann-Whitney test.(for non-parametrical variables). 476	
 Cluster 1 (n=12) Cluster 2 
(n=13) 
Cluster 3  (n=14) Cluster 4 (n=18) p-value 
Characteristics 
Age (y) 59.83 ±8.62 62.08 ± 10.84 61.21 ± 5.98 59.78 ± 8.13 0.87+ 
Current smokers 
(%) 
1.75 ± 0.45 1.85 ± 0.38 1.86 ± 0.36 1.72 ± 0.46 0.14♦ 
Dietary Data 
Energy (MJ) 8074.70 ± 211.65 8046.42±1738.6
3 
8347.50±1909.31 7387.47 ± 1838.73 0.54+ 
TE protein (%) 21.37 ± 1.97 20.55 ± 3.17 19.86 ± 4.04 21.12 ± 3.94 0.70+ 
TE carbohydrates 
(%) 
43.19 ± 7.02 40.57 ± 8.58 43.05 ± 8.27 41.90 ±7.03 0.83+ 
TE fat (%) 33.68 ± 6.60 37.31 ± 7.36 36.44 ± 6.26 36.22 ± 4.54 0.56+ 
Anthropometrical and biochemical parameters 
BMI (kg/m2) 28.17 ± 2.62 27.33 ± 2.78 33.56 ± 4.011,2,4 29.02 ± 3.86 <0.001+ 
Waist-hip ratio 0.94 ± 0.05 0.98 ± 0.03 0.99 ± 0.051 0.96 ± 0.04 0.01+ 
Heart Rate 
(beats/min) 
72.17 ± 11.85 69.69 ± 7.09 68.71 ± 10.71 68.78 ± 8.94 0.78+ 
Systolic blood 
pressure (mm Hg) 
124.58 ± 15.082,3,4 153.54 ± 17.58 143.14 ± 13.79 141.22 ± 12.06 <0.001+ 
Diastolic blood 
pressure (mm Hg) 
81.58 ± 9.1 79.23 ± 7.36 77.00 ± 9.14 84.50 ± 8.59 0.098+ 
CRP (mg/dL) 0.15 ± 0.09 0.27 ± 0.31 0.37 ± 0.291,4 0.14 ± 0.182,3 0.028♦ 
Glucose (mg/dL) 101.25 ± 20.87 119.92 ± 28.62 132.07 ± 53.841,4 95.22 ± 18.102,3 0.01♦ 
Diuresi 24h (mL) 1587.50 ± 621.35 1946.15 
±753.454 
1470.00 ± 441.46 1339.56±425.43 0.03+ 
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Plasmatic 
creatinine (mg/dL) 
1.01 ± 0.17 0.96  ± 0.19 1.02  ± 0.11 0.96  ± 0.11 0.52+ 
Uric acid (mg/dL) 6.58  ± 1.47 6.10  ± 0.85 6.89  ± 1.38 6.11  ± 0.78 0.19+ 
Na (mEq/L) 141.75  ± 2.14 141.15  ± 1.77 141.36  ± 2.06 140.72  ± 1.49 0.50+ 
K (mEq/L) 4.28  ± 0.23 4.19  ± 0.36 4.24  ± 0.33 3.90  ± 0.241,2,3 0.002+ 
P (mEq/L) 3.66  ± 0.612 3.02  ± 0.49 3.40  ± 0.58 3.09  ± 0.67 0.03+ 
Mg (mEq/L) 2.07  ± 0.19 2.21  ± 0.31 2.02  ± 0.15 2.12  ± 0.16 0.13+ 
Fe (mEq/L) 85.00  ± 23.65 99.38  ± 26.96 75.43  ± 21.18 94.89  ± 30.19 0.084+ 
Total cholesterol 
(mg/dL) 
243.83±36.282,3,4 189.69  ± 14.68 184.79  ± 20.79 203.28  ± 40.97 <0.001+ 
LDL cholesterol 
(mg/dL) 
167.33 ±32.822,3,4 116.92  ± 14.14 114.71  ± 17.87 137.67  ± 33.57 <0.001+ 
HDL cholesterol 
(mg/dL) 
48.92  ± 13.14 52.46  ± 9.98 37.86  ± 5.071,2 46.61  ± 10.09 0.003+ 
LDL 
cholesterol:HDL 
cholesterol ratio 
3.61  ± 1.06 2.31  ± 0.541,3,4 3.06  ± 0.50 2.98  ± 0.53 <0.001+ 
Triglycerides 
(mg/dL) 
138.17  ± 59.29 101.69  ± 33.27 160.71  ± 73.142,4 95.61  ± 35.28 0.03+ 
Apolipoprotein 
APOA1 (mg/dL) 
146.58  ± 23.36 157.92  ± 14.833 138.43  ± 15.16 147.33  ± 17.28 0.05+ 
Apolipoprotein 
APOB (mg/dL) 
136.42 ± 24.982,3,4 98.85  ± 13.37 103.36  ± 13.89 106.50  ± 19.96 <0.001+ 
APOB/A ratio 0.95  ± 0.232,3,4 0.63  ± 0.095 0.76  ± 0.15 0.72  ± 0.086 <0.001+ 
ASAT (UI/L) 30.08  ± 13.56 23.23  ± 4.92 28.14  ± 10.6 24.39  ± 6.05 0.203♦ 
ALAT (UI/L) 44.42  ± 41.39 26.15  ± 8.97 31.21  ± 16.33 28.83 ± 15.03 0.230♦ 
GGT (UI/L) 42.00  ± 33.68 26.08  ± 7.95 36.71  ± 25.78 27.22 ± 17.36 0.450♦ 
Bilirubin (mg/dL) 0.77  ± 0.31 0.85  ± 0.263 0.56  ± 0.122 0.73  ± 0.25 0.024♦ 
Alkaline 
phosphatase (UI/L) 
135.00  ± 20.69 162.54  ± 53.67 127.29  ± 31.30 135.28±34.03 0.082+ 
Lactate DH (UI/L) 327.83  ± 64.77 305.31  ± 16.25 340.50  ± 63.66 357.39±46.26 0.104+ 
Total proteins (g/L) 74.08  ± 2.64 73.46  ± 3.69 72.14  ± 2.69 69.94±2.751,2 0.001+ 
Albumin (g/L) 47.33  ± 1.92 47.31  ± 1.883,4 44.00  ± 2.77 43.39  ± 1.82 <0.001+ 
Albumin (%) 65.87  ± 2.11 64.79  ± 2.49 60.32  ± 3.821,2,4 63.36  ± 2.53 <0.001+ 
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 α1 globulin  (%) 2.76  ± 0.223,4 3.10  ± 0.46 3.53  ± 0.48 3.27  ± 0.62 0.002+ 
α2 globulin (%) 5.93  ± 0.742,3,4 7.39  ± 1.14 9.10  ± 1.621,2,4 7.25  ± 1.49 <0.001+ 
Β globulin (%) 11.19  ± 0.76 11.21  ± 1.28 12.80  ± 1.831,2,4 11.02  ± 0.87 0.001+ 
Γ globulin (%) 14.25  ± 1.99 13.52  ± 2.04 14.25  ± 2.68 15.10  ± 1.77 0.25+ 
Albumin:globulin 
ratio 
1.94  ± 0.18 1.85  ± 0.21 1.54  ± 0.241,2,4 1.74  ± 0.19 <0.001+ 
Ferritine(ng/mL) 167.92  ± 102.02 187.85  ± 
166.93 
179.07  ± 144.77 208.56±152.61 0.89+ 
Folic acid  (serum) 
(ng/mL) 
9.50  ± 3.43 10.98  ± 2.79 8.51  ± 3.52 10.27  ± 4.65 0.36+ 
Intraerythrocytary 
folic acid (ng/mL) 
333.27  ± 79.13 401.54  ± 69.95 417.57  ± 107.39 374.38  ± 80.27 0.08+ 
Vitamin B-12 
(pg/mL) 
525.58  ± 368.70 428.85  ± 
145.05 
377.07  ± 139.37 380.44 ±110.63 0.29♦ 
Homocysteine 
(µmol /L) 
11.07  ± 2.60 11.17  ± 1.241,2,4 14.31  ± 4.28 11.26  ± 1.79 0.005+ 
Hemoglobin 
concentration (g/L) 
152.75  ± 9.92 151.00  ± 11.77 143.57  ± 9.15 147.33  ± 8.09 0.08+ 
Hematocrit (L/L) 0.45  ± 0.03 0.45  ± 0.03 0.43  ± 0.03 0.44  ± 0.025 0.16+ 
Erythrocyte mean 
corpuscular volume 
(fL) 
89.80  ± 2.59 91.05  ± 3.73 90.35  ± 5.30 88.78  ± 3.35 0.42+ 
Mean corpuscular 
hemoglobin (pg) 
30.20  ± 0.93 30.82  ± 0.98 30.31  ± 1.89  29.88  ± 1.16 0.28+ 
Mean corpuscular 
hemoglobin 
concentration (g/L) 
336.25  ± 5.15 338.45  ± 4.74 335.57  ± 7.44 336.56  ± 9.99 0.78+ 
Erytrocyte 
sedimentation rate 
(mm/h) 
7.08  ± 4.44 8.08  ± 3.86 11.07  ± 5.261,4 5.44  ± 2.312,3 0.003♦ 
Reed distribution 
width (%) 
13.06  ± 0.584 13.17  ± 0.59 13.59  ± 0.66 13.68  ± 0.53 0.01+ 
Hemoglobin 
distribution width 
(g/L) 
25.74  ± 1.46 24.49  ± 1.96 25.51  ± 2.65 26.03  ± 2.18 0.24+ 
Platelet count 
(x109/L) 
282.17  ± 56.364 233.54  ± 45.98 264.64  ± 63.99 220.17  ± 33.78 0.006+ 
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All values are mean ± SD, p-values are based on simple ANOVA test (+) for parametric variables and 477	
Kruskall Wallis test (♦) for non-parametric variables, (p<0.05 for both tests); Superscript numbers 478	
adjacent to values from each cluster denote a significant difference between indicated cluster number 479	
based on Tukey post-hoc test (for parametrical variables) and Mann-Whitney test.(for non-parametrical 480	
variables). TE protein %: protein as percentage of total energy intake; TE carbohydrate%: carbohydrate as 481	
percentage of total energy intake; TE fat %: fat as percentage of total energy intake. PCR: c-reactive 482	
protein; BMI: body mass index; ASAT: aspartate aminotranspherase; ALAT: alanine aminotransferase; 483	
GGT:gamma-glutamyl transpeptidase; Na: sodium; K: potassium; P: phosphorous; Mg: Magnessium; Fe: 484	
iron. DH: dehydrogenase;  485	
 486	
Mean platelet 
volume (fL) 
8.27  ± 0.47 9.11  ± 0.74 8.85  ± 0.72 8.89  ± 0.99 0.05+ 
Leucocyte count  
(x109/L) 
6.84  ± 1.73 7.09  ± 0.88 7.96  ± 1.234 6.15  ± 1.30 0.004+ 
Neutrophils (%) 50.45  ± 5.822,3,4 63.84  ± 8.78 58.26  ± 4.43 58.21  ± 6.32 <0.001+ 
Lymphocytes (%) 35.83  ± 4.422,4 24.90  ± 7.07 29.90  ± 5.06 29.83  ± 5.87 <0.001+ 
Monocytes (%) 6.58  ± 1.07 5.85  ± 1.09 6.44  ± 0.88 7.47  ± 0.632,3 <0.001+ 
Eosinophils (%) 4.12  ± 2.042,4 2.65  ± 1.23 2.77 ± 1.19 2.15  ± 0.72 0.002+ 
Basophils (%) 0.71  ± 0.25 0.79  ± 0.394 0.57 ± 0.2 0.49  ± 0.19 0.01+ 
Unclassified cells 
(%) 
2.16  ± 0.95 1.99  ± 0.93 2.05 ± 0.50 1.86  ± 0.56 0.726+ 
Neutrophils ( 
x109/L) 
3.49  ± 1.11 4.55  ± 0.891,4 4.63  ± 0.791,4 3.56  ± 0.84 0.001+ 
Lymphocytes ( 
x109/L) 
2.43  ± 0.612,4 1.75  ± 0.461,3 2.39  ± 0.562,4 1.85  ± 0.57 0.002+ 
Monocytes ( x109/L) 0.45  ± 0.12 0.42  ± 0.10 0.52  ± 0.13 0.45  ± 0.10 0.24♦ 
Eosinophil ( x109/L) 0.27  ± 0.15 0.19  ± 0.086 0.21  ± 0.09 0.13  ± 0.051,2,3 0.001♦ 
Basophils ( x109/L) 0.05  ± 0.03 0.05  ± 0.04 0.03  ± 0.04 0.08  ± 0.011,2 0.002♦ 
Unclassified cells ( 
x109/L) 
0.16  ± 0.06 0.15  ± 0.06 0.17  ± 0.054 0.11  ± 0.051,3 0.029♦ 
Prothrombin time 
(%) 
97.58  ± 3.684 95.54  ± 5.72 96.00  ± 4.93 92.50  ± 5.83 0.126♦ 
Prothrombin time 
(seg) 
13.07  ± 0.45 13.23  ± 0.78 13.29  ± 0.47 13.56  ± 0.67 0.186+ 
Thromboplastin 
partial time (seg) 
28.48  ± 0.89 26.65  ± 7.97  26.38  ± 7.55 29.35  ± 2.11 0.386+ 
Fibrinogen (g/L) 3.18  ± 0.51 4.08  ± 0.821,4 3.73  ± 0.62 3.18  ± 0.37 <0.001+ 
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Table 2. Urinary excretion amounts [mmols, 24h-urine] of metabolites after ANOVA analysis, in parenthesis µM/mM creatinine. OD-c_BAS: obese and 487	
diabetic cluster in basal period; H-c_BAS: healthier cluster in basal period; OD-c_WPI: obese and diabetic cluster after wine polyphenols intake; H-c_WPI: 488	
healthier cluster after wine polyphenol intake. WPI: wine polyphenols intake; MTP: metabotype.4-HPA: 4-hydroxyphenylacetate; 3-HPA: 3-489	
hydroxyphenylacetate. DMA: dimethylamine. 490	
  491	
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MEAN ± SEM; mmols, 24h  
(µM/mM creatinine) 
Metabolite OD-c_BAS H-c_BAS OD-c_WPI H-c_WPI p-value FDR  p-value  
Metabolite 
information 
 
Tartrate 0.140 ± 0.052  
(14.16 ± 5.78)  
0.451 ± 0.019 
(39.83 ± 14.74) 
1.065 ± 0.19  
(84.57 ± 14.58) 
1.292 ± 0.285 
(107.89 ± 16.69) 
7.09E-07 6.02E-05 WPI 
Glucose 14.044 ± 7.562 
(2157.79 ± 1108.56) 
0.210 ± 0.019 
(19.95 ± 1.61) 
13.786± 7.850 
(1613.70 ± 1042.12) 
0.188± 0.038 
(16.53 ± 2.08) 
0.0001 0.005 MTP 
4-HPA 0.170 ± 0.025 
(17.23 ± 2.04) 
0.163 ± 0.013 
(15.52 ± 1.13) 
0.184 ± 0.022 
(16.23 ± 1.95) 
0.280 ± 0.029 
(25.35 ± 1.48) 
0.0008 0.02 WPI-MTP 
3-HPA 0.056 ± 0.01 
(40.71± 8.34) 
0.062 ± 0.005 
(48.39± 3.99) 
0.0856 ± 0.016 
(56.04± 10.97) 
0.101 ± 0.012 
(75.7± 10.43) 
0.01 0.18 WPI 
Mannitol 0.556 ± 0.112 
(462.62+142.13) 
0.782 ± 0.144 
(646.87± 132.08) 
1.223 ± 0.157 
(804.66± 117.30) 
1.312 ± 0.255 
(957.04± 210.15) 
0.005 0.99 WPI 
Threonine 0.094 ± 0.014 
(9.07 ± 1.17) 
0.107 ± 0.013 
(10.33 ± 1.51) 
0.141 ± 0.013 
(12.64 ± 2.19) 
0.173 ± 0.032 
(15.00 ± 1.99) 
0.02 0.18 WPI 
Methanol 0.473 ± 0.077 
(46.83 ± 6.80) 
0.436 ± 0.050 
(39.99 ± 3.72) 
0.682 ± 0.133 
(51.02 ± 5.07) 
0.676 ± 0.076 
(59.91 ± 3.82) 
0.03 0.30 WPI 
Fucose 0.32 ± 0.04 
(30.58 ± 2.36) 
0.327 ± 0.023 
(30.55 ± 1.81) 
0.503 ± 0.069 
(39.01 ± 4.56) 
0.495 ± 0.081 
(42.84 ± 3.87) 
0.04 0.31 WPI 
Lactate 0.516 ± 0.19 
(65.56 ± 34.17) 
0.212 ± 0.075 
(19.77 ± 1.37) 
0.432 ± 0.087 
(37.83 ± 11.02) 
0.294 ± 0.030 
(26.09 ± 1.80) 
0.04 0.33 MTP 
Betaine 0.549 ± 0.217 
(56.01 ± 21.61) 
0.207 ± 0.030 
(19.36 ± 2.64) 
0.676 ± 0.245 
(53.77 ± 18.74) 
0.214 ± 0.037 
(18.83 ± 2.28) 
0.02 0.18 MTP 
DMA 0.469 ± 0.021 
(51.68 ± 7.82) 
0.503 ± 0.048 
(45.89 ± 3.20) 
0.905 ± 0.230 
(65.36 ± 8.11) 
0.568 ± 0.078 
(51.21 ± 4.62) 
0.02 0.18 MTP 
492	
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FIGURE LEGEND 493	
 494	
   Figure 1. Methodological strategy steps followed in the present study. CVD: cardiovascular disease; c: cluster; OD-c: obese and diabetic cluster; H-c: 495	
healthier cluster. OSC-PLS-DA: partial least-squares discriminant analysis with orthogonal signal correction. EGA: equivalents of gallic acid496	
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 497	
Figure 2. Box-plots of the metabolites derived from ANOVA test (p<0.05 after FDR 498	
correction). Different letters indicate significant differences between interventions. OD-c_BAS: 499	
obese and diabetic cluster in basal period; H-c_BAS: healthier cluster in basal period; OD-500	
c_WPI: obese and diabetic cluster after wine polyphenols intake; H-c_WPI: healthier cluster 501	
after wine polyphenols intake.  502	
